Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Combination Rule” Trips Up QRxPharma’s Moxduo

Executive Summary

Morphine/oxycodone fixed-dose product must offer efficacy or safety advantage over individual drug components because the two opioids are not generally used together to treat acute pain, agency says; QRxPharma fails to convince advisory committee that respiratory safety advantage exists.

Advertisement

Related Content

Moxduo Must Show Clear Benefit Over Opioid Components, FDA Says
QRxPharma Given Statistical Leeway With Moxduo, To No Avail
QRxPharma Given Statistical Leeway With Moxduo, To No Avail
FDA Draws Regulatory Line Between Moxduo, HIV Combos
FDA Draws Regulatory Line Between Moxduo, HIV Combos

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel